{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T12:46:01Z","timestamp":1789994761702,"version":"4.0.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T00:00:00Z","timestamp":1557964800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T00:00:00Z","timestamp":1557964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s40262-019-00772-2","type":"journal-article","created":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T02:29:13Z","timestamp":1557973753000},"page":"1497-1504","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["The Effect of Food Intake on the Pharmacokinetics of Oral Basal Insulin: A Randomised Crossover Trial in Healthy Male Subjects"],"prefix":"10.1007","volume":"58","author":[{"given":"Inge B.","family":"Halberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karsten","family":"Lyby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karsten","family":"Wassermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Heise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leona","family":"Plum-M\u00f6rschel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Zijlstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,16]]},"reference":[{"key":"772_CR1","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1177\/193229680900300323","volume":"3","author":"L Heinemann","year":"2009","unstructured":"Heinemann L, Jacques Y. Oral insulin and buccal insulin: a critical reappraisal. J Diabetes Sci Technol. 2009;3:568\u201384.","journal-title":"J Diabetes Sci Technol."},{"key":"772_CR2","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/j.1463-1326.2009.01150.x","volume":"12","author":"H Iyer","year":"2010","unstructured":"Iyer H, Khedkar A, Verma M. Oral insulin\u2014a review of current status. Diabetes Obes Metab. 2010;12:179\u201385.","journal-title":"Diabetes Obes Metab."},{"key":"772_CR3","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1177\/1932296814529988","volume":"8","author":"E Zijlstra","year":"2014","unstructured":"Zijlstra E, Heinemann L, Plum-M\u00f6rschel L. Oral insulin reloaded: a structured approach. J Diabetes Sci Technol. 2014;8:458\u201365.","journal-title":"J Diabetes Sci Technol."},{"key":"772_CR4","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1111\/jphp.12607","volume":"68","author":"CY Wong","year":"2016","unstructured":"Wong CY, Martinez J, Dass CR. Oral delivery of insulin for treatment of diabetes: status quo, challenges and opportunities. J Pharm Pharmacol. 2016;68:1093\u2013108.","journal-title":"J Pharm Pharmacol."},{"key":"772_CR5","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/nrd1067","volume":"2","author":"M Goldberg","year":"2003","unstructured":"Goldberg M, Gomez-Orellana I. Challenges for the oral delivery of macromolecules. Nat Rev Drug Discov. 2003;2:289\u201395.","journal-title":"Nat Rev Drug Discov."},{"key":"772_CR6","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.addr.2016.02.004","volume":"106","author":"TA Aguirre","year":"2016","unstructured":"Aguirre TA, Teijeiro-Osorio D, Rosa M, Coulter IS, Alonso MJ, Brayden DJ. Current status of selected oral peptide technologies in advanced preclinical development and in clinical trials. Adv Drug Deliv Rev. 2016;106:223\u201341.","journal-title":"Adv Drug Deliv Rev."},{"key":"772_CR7","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.4155\/tde.11.132","volume":"2","author":"EG Walsh","year":"2011","unstructured":"Walsh EG, Adamczyk BE, Chalasani KB, Maher S, O\u2019Toole EB, Fox JS, et al. Oral delivery of macromolecules: rationale underpinning Gastrointestinal Permeation Enhancement Technology (GIPET). Ther Deliv. 2011;2:1595\u2013610.","journal-title":"Ther Deliv."},{"key":"772_CR8","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S2213-8587(18)30372-3","volume":"7","author":"IB Halberg","year":"2019","unstructured":"Halberg IB, Lyby K, Wassermann K, Heise T, Zijlstra E, Plum-M\u00f6rschel L. Efficacy and safety of oral basal insulin versus subcutaneous insulin glargine in subjects with type 2 diabetes: an 8-week, randomised, double-blind phase 2 trial. Lancet Diabetes Endocrinol. 2019;7:179\u201388.","journal-title":"Lancet Diabetes Endocrinol."},{"key":"772_CR9","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/j.addr.2009.09.006","volume":"61","author":"S Maher","year":"2009","unstructured":"Maher S, Leonard TW, Jacobsen J, Brayden DJ. Safety and efficacy of sodium caprate in promoting oral drug absorption: from in vitro to the clinic. Adv Drug Deliv Rev. 2009;61:1427\u201349.","journal-title":"Adv Drug Deliv Rev."},{"key":"772_CR10","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.2165\/00003495-200262100-00005","volume":"62","author":"LE Schmidt","year":"2002","unstructured":"Schmidt LE, Dalhoff K. Food\u2013drug interactions. Drugs. 2002;62:1481\u2013502.","journal-title":"Drugs."},{"key":"772_CR11","unstructured":"European Medicines Agency. Committee for Human Medicinal Products. Guideline on the investigation of drug interactions. 2012. https:\/\/www.ema.europa.eu\/documents\/scientific-guideline\/guideline-investigation-drug-interactions_en.pdf. Accessed 16 Apr 2019."},{"key":"772_CR12","unstructured":"U.S. Food and Drug Administration. Guidance for Industry. Food-effect bioavailability and fed bioequivalence studies. 2002. https:\/\/www.fda.gov\/media\/70945\/download. Accessed 16 Apr 2019."},{"key":"772_CR13","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.2337\/dc12-2480","volume":"36","author":"ER Seaquist","year":"2013","unstructured":"Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care. 2013;36:1384\u201395.","journal-title":"Diabetes Care."},{"issue":"Suppl 1","key":"772_CR14","first-page":"A141","volume":"59","author":"R Eldor","year":"2010","unstructured":"Eldor R, Arbit E, Miteva Y, Freier R, Kidron M. Oral insulin: type I diabetes (T1DM) patient response upon preprandial administration. Diabetes. 2010;59(Suppl 1):A141 (Abstract).","journal-title":"Diabetes."},{"key":"772_CR15","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1472-6904-8-5","volume":"8","author":"MA Karsdal","year":"2008","unstructured":"Karsdal MA, Byrjalsen I, Riis BJ, Christiansen C. Optimizing bioavailability of oral administration of small peptides through pharmacokinetic and pharmacodynamic parameters: the effect of water and timing of meal intake on oral delivery of salmon calcitonin. BMC Clin Pharmacol. 2008;8:5.","journal-title":"BMC Clin Pharmacol."},{"key":"772_CR16","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/j.1365-2125.2009.03371.x","volume":"67","author":"MA Karsdal","year":"2009","unstructured":"Karsdal MA, Byrjalsen I, Azria M, Arnold M, Choi L, Riis BJ, et al. Influence of food intake on the bioavailability and efficacy of oral calcitonin. Br J Clin Pharmacol. 2009;67:413\u201320.","journal-title":"Br J Clin Pharmacol."},{"issue":"Suppl 1","key":"772_CR17","first-page":"A315","volume":"66","author":"TA B\u00e6kdal","year":"2017","unstructured":"B\u00e6kdal TA, Borregaard J, Donsmark M, Breitschaft A, S\u00f8ndergaard FL. Evaluation of the effects of water volume with dosing and post-dose fasting period on pharmacokinetics of oral semaglutide. Diabetes. 2017;66(Suppl 1):A315 (Abstract).","journal-title":"Diabetes."},{"key":"772_CR18","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/j.1464-5491.2004.01160.x","volume":"21","author":"M Kidron","year":"2004","unstructured":"Kidron M, Dinh S, Menachem Y, Abbas R, Variano B, Goldberg M, et al. A novel per-oral insulin formulation: proof of concept study in non-diabetic subjects. Diabet Med. 2004;21:354\u20137.","journal-title":"Diabet Med."},{"issue":"Suppl 1","key":"772_CR19","first-page":"A103","volume":"54","author":"T Heise","year":"2005","unstructured":"Heise T, Nosek L, Arbit E, et al. Reduction of postprandial blood glucose excursions by an optimized formulation of oral insulin. Diabetes. 2005;54(Suppl 1):A103 (Abstract).","journal-title":"Diabetes."},{"key":"772_CR20","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/j.1463-1326.2009.01146.x","volume":"12","author":"SD Luzio","year":"2010","unstructured":"Luzio SD, Dunseath G, Lockett A, Broke-Smith TP, New RR, Owens DR. The glucose lowering effect of an oral insulin (Capsulin) during an isoglycaemic clamp study in persons with type 2 diabetes. Diabetes Obes Metab. 2010;12:82\u20137.","journal-title":"Diabetes Obes Metab."},{"key":"772_CR21","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/j.1463-1326.2010.01213.x","volume":"12","author":"A Khedkar","year":"2010","unstructured":"Khedkar A, Iyer H, Anand A, Verma M, Krishnamurthy S, Savale S, et al. A dose range finding study of novel oral insulin (IN-105) under fed conditions in type 2 diabetes mellitus subjects. Diabetes Obes Metab. 2010;12:659\u201364.","journal-title":"Diabetes Obes Metab."},{"key":"772_CR22","first-page":"1","volume":"6","author":"AJ Chakera","year":"2012","unstructured":"Chakera AJ, Pearce SH, Vaidya B. Treatment for primary hypothyroidism: current approaches and future possibilities. Drug Des Devel Ther. 2012;6:1\u201311.","journal-title":"Drug Des Devel Ther."},{"key":"772_CR23","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.2337\/dc09-1807","volume":"33","author":"C Kapitza","year":"2010","unstructured":"Kapitza C, Zijlstra E, Heinemann L, Castelli MC, Riley G, Heise T. Oral insulin: a comparison with subcutaneous regular human insulin in patients with type 2 diabetes. Diabetes Care. 2010;33:1288\u201390.","journal-title":"Diabetes Care."},{"key":"772_CR24","unstructured":"European Medicines Agency. Committee for Medicinal Products for Human Use. Guideline on the investigation of bioequivalence. 2010. https:\/\/www.ema.europa.eu\/documents\/scientific-guideline\/guideline-investigation-bioequivalence-rev1_en.pdf. Accessed 16 Apr 2019."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-019-00772-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-019-00772-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-019-00772-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T17:26:23Z","timestamp":1628616383000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-019-00772-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,16]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["772"],"URL":"https:\/\/doi.org\/10.1007\/s40262-019-00772-2","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,16]]},"assertion":[{"value":"16 May 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and informed consent"}},{"value":"This trial was funded by Novo Nordisk.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Inge B. Halberg, Karsten Lyby and Karsten Wassermann are employees and shareholders of Novo Nordisk. Tim Heise is a shareholder of Profil, which has received research funds from Adocia, Boehringer Ingelheim, Dance Pharmaceuticals, Eli Lilly, Johnson & Johnson, MedImmune, Merck Sharp and Dohme, Mylan, Nordic Bioscience, Novo Nordisk, Poxel, Roche Diagnostics, Saniona, Sanofi, Senseonics and Zealand Pharma. In addition, Tim Heise is member of advisory panels for Novo Nordisk and Mylan and received speaker honoraria and travel grants from Dexcom, Eli Lilly, Mylan, Novo Nordisk, Sanofi and Zealand Pharma. Leona Plum-M\u00f6rschel has received speaker honoraria and travel grants from Eli Lilly and Novo Nordisk. Eric Zijlstra has received speaker honoraria and travel grants from Novo Nordisk, Roche Diabetes Care and Senseonics.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The trial was registered at ClinicalTrials.gov (trial identifier: NCT02304627).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Trial registration"}},{"value":"Individual participant data will be shared in datasets in a de-identified\/anonymised format with bona fide researchers submitting a research proposal requesting access to data for use as approved by the Independent Review Board (IRB) according to the IRB Charter (see ). Datasets from Novo Nordisk-sponsored clinical research completed after 2001 for product indications approved in both the EU and USA and study protocol and redacted Clinical Study Report (CSR) will be available according to Novo Nordisk data-sharing commitments. The data will be available permanently after research completion and approval of product and product use in both the EU and USA (no end date). The access request proposal form and the access criteria can be found at . The data will be made available on a specialised SAS<sup>\u00ae<\/sup> data platform.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}}]}}